GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$179.38
−2.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$183.02
From 52W high−2.03%
Volume3.04M
Market cap$24.07B
P/E (TTM)—
P/S (TTM)20.3x
Div yield—
Key dataSep 18, 2026
Open
$183.02
From 52W high
−2.03%
Volume
3.04M
Market cap
$24.07B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−60.1x
P/E (TTM)
—
RSI (14)
62.0
MomentumView details →
1D Return
−2.03%
YTD Return
+74.58%
SummaryUpdated Jun 1, 2026
Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company founded in 2011 and headquartered in Redwood City, California. The company went public in October 2018 and has established itself as a leader in liquid biopsy technology, which uses blood tests to detect and analyze cancer-related genetic material. Guardant Health operates primarily in the United States with expanding international presence, serving oncologists, patients, and biopharmaceutical companies with innovative blood-based cancer testing solutions.
Similar companies
Latest newsMore news →
EviCore by Evernorth added Guardant Health's Shield blood test for colorectal cancer screening to its clinical guidelines, effective January 1, 2027.6d agoCallan Family Office LLC acquired a new stake in Guardant Health, Inc. by purchasing 6,080 shares valued at approximately $912,000 in the second quarter, as disclosed in its 13F filing.26d ago